JP2010511382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511382A5 JP2010511382A5 JP2009539218A JP2009539218A JP2010511382A5 JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5 JP 2009539218 A JP2009539218 A JP 2009539218A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2010511382 A5 JP2010511382 A5 JP 2010511382A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ack1
- amino acid
- nucleic acid
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 claims 30
- 102000020233 phosphotransferase Human genes 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 150000001413 amino acids Chemical class 0.000 claims 29
- 235000001014 amino acid Nutrition 0.000 claims 25
- 229940024606 amino acid Drugs 0.000 claims 25
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims 24
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 14
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 14
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims 13
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 claims 12
- 102000001253 Protein Kinase Human genes 0.000 claims 11
- 108060006633 protein kinase Proteins 0.000 claims 11
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 9
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 9
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 claims 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 8
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims 8
- 239000002853 nucleic acid probe Substances 0.000 claims 8
- 101150052413 TNK2 gene Proteins 0.000 claims 5
- 101150098329 Tyro3 gene Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 230000001131 transforming effect Effects 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 229930014626 natural product Natural products 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 102220539799 Fibroblast growth factor receptor 4_V10I_mutation Human genes 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000001850 reproductive effect Effects 0.000 claims 3
- 102220198375 rs1057520036 Human genes 0.000 claims 3
- 102200111635 rs13433937 Human genes 0.000 claims 3
- 102200143304 rs351855 Human genes 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102200074429 rs104894784 Human genes 0.000 claims 2
- 102220304248 rs1243381790 Human genes 0.000 claims 2
- 102200118192 rs33940204 Human genes 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000001842 enterocyte Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86817306P | 2006-12-01 | 2006-12-01 | |
| PCT/SG2007/000412 WO2008066498A1 (en) | 2006-12-01 | 2007-12-03 | Cancer-related protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511382A JP2010511382A (ja) | 2010-04-15 |
| JP2010511382A5 true JP2010511382A5 (OSRAM) | 2011-01-27 |
Family
ID=39468190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539218A Pending JP2010511382A (ja) | 2006-12-01 | 2007-12-03 | 癌関連タンパク質キナーゼ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110008347A1 (OSRAM) |
| EP (1) | EP2094850B1 (OSRAM) |
| JP (1) | JP2010511382A (OSRAM) |
| SG (1) | SG177225A1 (OSRAM) |
| WO (1) | WO2008066498A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| WO2008089035A1 (en) * | 2007-01-11 | 2008-07-24 | Genentech, Inc. | Genetic variations associated with tumors |
| CN101848998B (zh) | 2007-08-30 | 2016-08-03 | 第一三共株式会社 | 抗epha2抗体 |
| WO2009087462A2 (en) * | 2007-12-24 | 2009-07-16 | Oxford Biotherapeutics Ltd. | Ephrin type-a receptor 10 protein |
| EP2252373B1 (en) * | 2008-02-05 | 2012-06-13 | Urifer Ltd | Novel fer -like protein, pharmaceutical compositions containing it and method for its use |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2165710A1 (en) * | 2008-09-19 | 2010-03-24 | Institut Curie | Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| EP2169071A1 (en) * | 2008-09-29 | 2010-03-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rodent cancer model for human FGFR4 Arg388 polymorphism |
| EA201990619A1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Fgf21 мутанты и их применение |
| WO2010048304A2 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| KR20240091315A (ko) | 2008-11-12 | 2024-06-21 | 인리젠 | 분리된 신장 세포 및 이의 용도 |
| DK2881402T3 (en) | 2009-02-12 | 2017-08-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| SG10201402038WA (en) | 2009-05-05 | 2014-07-30 | Amgen Inc | FGF21 Mutants And Uses Thereof |
| EP2336171A1 (en) * | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| NZ603482A (en) | 2010-05-12 | 2014-11-28 | Tengion Inc | Bioactive renal cells |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012068073A2 (en) | 2010-11-15 | 2012-05-24 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting tnk-1 |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| AU2012346540C1 (en) * | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| CN120514834A (zh) | 2014-03-28 | 2025-08-22 | 华盛顿大学商业中心 | 乳腺癌和卵巢癌疫苗 |
| US11946934B2 (en) | 2014-09-03 | 2024-04-02 | Wellmarker Bio Co., Ltd. | Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof |
| US9994914B2 (en) | 2014-10-09 | 2018-06-12 | Roche Molecular Systems, Inc. | Mutation in the epidermal growth factor receptor kinase domain |
| MA43943A (fr) * | 2015-05-29 | 2018-12-12 | Ignyta Inc | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk |
| CA3002560A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| BR112018014615A2 (pt) | 2016-01-20 | 2018-12-11 | The Scripps Research Institute | composições de anticorpo para ror1 e métodos relacionados |
| US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
| CN106480205A (zh) * | 2016-11-11 | 2017-03-08 | 北京吉因加科技有限公司 | 用于同时检测多种突变类型的序列组合和探针 |
| EP3654952A1 (en) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| SG11202000846WA (en) | 2017-08-07 | 2020-02-27 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| US12077599B2 (en) * | 2017-11-29 | 2024-09-03 | Seoul National University R&Db Foundation, National Cancer Center | Anti-ROS1 antibody and use thereof |
| WO2019133752A1 (en) * | 2017-12-28 | 2019-07-04 | Development Center For Biotechnology | A method for predicting drug efficacy |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| US20220162572A1 (en) * | 2019-03-04 | 2022-05-26 | Tokyo Metropolitan Institute Of Medical Science | NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF |
| CN110031626A (zh) * | 2019-04-02 | 2019-07-19 | 浙江理工大学 | 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| US12264149B2 (en) | 2020-12-30 | 2025-04-01 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| MX2023009954A (es) | 2021-02-26 | 2023-11-09 | Tyra Biosciences Inc | Compuestos de aminopirimidina y métodos de uso de estos. |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| AU2023300362A1 (en) | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202535368A (zh) | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| DE3069468D1 (en) * | 1979-12-19 | 1984-11-22 | Nat Res Dev | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3611194A1 (de) * | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) * | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SE517975C2 (sv) | 2000-05-30 | 2002-08-13 | Power Ab C | Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion |
| AU2002213084A1 (en) * | 2000-10-11 | 2002-04-22 | Avalon Pharmaceuticals | Cancer-linked genes as targets for chemotherapy |
| US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| AU2003225535A1 (en) * | 2002-01-31 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| JP2006174701A (ja) * | 2003-02-24 | 2006-07-06 | Research Association For Biotechnology | 新規タンパク質およびそれをコードするｄｎａ |
| JP2005198640A (ja) * | 2003-11-25 | 2005-07-28 | Biomarker Science:Kk | 遺伝子発現方法 |
-
2007
- 2007-12-03 WO PCT/SG2007/000412 patent/WO2008066498A1/en not_active Ceased
- 2007-12-03 US US12/517,050 patent/US20110008347A1/en not_active Abandoned
- 2007-12-03 JP JP2009539218A patent/JP2010511382A/ja active Pending
- 2007-12-03 SG SG2011095569A patent/SG177225A1/en unknown
- 2007-12-03 EP EP07852282.8A patent/EP2094850B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511382A5 (OSRAM) | ||
| JP6076581B2 (ja) | Ｔｉａｂｓを検出するための組成物及び方法 | |
| JP6352924B2 (ja) | ダイナミックｂｈ３プロファイリング | |
| JP2019176878A (ja) | Ｄｎａ−蛋白質複合体の組成物 | |
| KR20080114689A (ko) | 증가된 ｂｃｌ-2에 의한 암의 발견 | |
| JP2012115275A5 (OSRAM) | ||
| JP2008249727A5 (OSRAM) | ||
| JP2011506941A5 (OSRAM) | ||
| WO2015184443A1 (en) | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy | |
| AU2014224727A1 (en) | Methods and compositions for the diagnosis of Alzheimer's disease | |
| JP2008509673A5 (OSRAM) | ||
| US20230417742A1 (en) | Improved assays to detect nucleosome modifications using antibody-targeted enzyme digestion | |
| JP2011517937A5 (OSRAM) | ||
| JP2021510306A (ja) | ゲノム遺伝子座におけるヌクレオソーム修飾及び変異の定量化のための方法並びにその臨床応用 | |
| JP2009539370A5 (OSRAM) | ||
| CN111480079A (zh) | 疾病蛋白质组蛋白质阵列及其应用 | |
| KR101227434B1 (ko) | 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용 | |
| CA2687937C (en) | Novel gpiiia gene | |
| US20140065610A1 (en) | Method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders | |
| CN104650214B (zh) | 肺动脉高压致病基因acvrl1突变位点及其应用 | |
| EP1880024A2 (en) | Polymorphic ghsr nucleic acids and uses thereof | |
| KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
| JP2009535033A5 (OSRAM) | ||
| US10745439B2 (en) | Kinase substrates and methods of use thereof | |
| US20140094384A1 (en) | Stromal antigen 2 (stag2) compositions and methods |